Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emtricitabine, (+/-)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | POLG | P54098 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.63 |
| ▸ | DCK | P27707 | 7/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine SCHEMBL267686 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3230512 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12202574 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6903677 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL5427218 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6362885 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3722124 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL39708 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL22413085 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12662838 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4353 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-3212200-B2 | USE OF AN INVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT AND PREVENTION OF DEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2025-12-24 | — | — | EP | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250283074-A1 | CLUSTERIN OVEREXPRESSION IN ALZHEIMER’S DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-11 | — | — | US | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| WO-1995007086-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1995-03-16 | — | — | WO | claimed |
| WO-1994009793-A1 | ENANTIOMERICALLY PURE β-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0575482-A1 | ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE | EMORY UNIVERSITY (US) | 1993-12-29 | — | — | EP | claimed |
| EP-0574487-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-22 | — | — | EP | claimed |
| EP-0574457-A1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-22 | — | — | EP | claimed |
| US-5234913-A | Synergistic mixture of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocystosine and zidovudine | BURROUGHS WELLCOME CO. (US) | 1993-08-10 | — | — | US | claimed |
| EP-0526253-A1 | 1,3-Oxathiolane nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 1993-02-03 | — | — | EP | claimed |
| WO-1992015309-A1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| WO-1992015308-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| WO-1992014743-A2 | ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE | EMORY UNIVERSITY (US) | 1992-09-03 | — | — | WO | claimed |